Procedure
group2
group2 is a medical procedure with 4 clinical trials. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
PROCEDURE
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
0(0%)
Results Posted
0%(0 trials)
Phase Distribution
Ph not_applicable
3
75%
Ph phase_3
1
25%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 3Large-scale testing
1(25.0%)
N/ANon-phased studies
3(75.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
0
trials recruiting
Total Trials
4
all time
Status Distribution
Completed(3)
Other(1)
Detailed Status
Completed3
unknown1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 31 (25.0%)
N/A3 (75.0%)
Trials by Status
completed375%
unknown125%
Recent Activity
0 active trials
Showing 4 of 4
unknownnot_applicable
Effects of Peas on Blood Glucose Control
NCT02552823
completednot_applicable
Real-time Identification of the Aberrant Left Hepatic Arterial Territory in the Liver Using Near-infrared Fluorescence Imaging
NCT05971069
completednot_applicable
The Children's WEAR Trial(Phase 1&2)
NCT01704729
completedphase_3
Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients
NCT00190242
Clinical Trials (4)
Showing 4 of 4 trials
NCT02552823Not Applicable
Effects of Peas on Blood Glucose Control
NCT05971069Not Applicable
Real-time Identification of the Aberrant Left Hepatic Arterial Territory in the Liver Using Near-infrared Fluorescence Imaging
NCT01704729Not Applicable
The Children's WEAR Trial(Phase 1&2)
NCT00190242Phase 3
Immunogenicity and Tolerance of Two Strategies of Anti-HAV Vaccination in HIV-infected Patients
All 4 trials loaded
Drug Details
- Intervention Type
- PROCEDURE
- Total Trials
- 4